Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen, Inc.    AMGN

Delayed Quote. Delayed  - 09/28 08:39:15 pm
169.505 USD   -1.24%
09/27 NASDAQ 100 MOVE : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27 AMGEN : Announces Top-Line Results From Phase 3 KYPROLIS« (Carfilzom..
News SummaryMost relevantAll newsSector news 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2012 | 10:40pm CEST

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on AMGEN, INC.
01:16p AMGEN : Assigned Patent
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/27 AMGEN : Announces Top-Line Results From Phase 3 KYPROLIS« (Carfilzomib) CLARION ..
09/26 AMGEN : Opens Nomination Process For LabCentral Residency
09/26 AMGEN : And UCB Announce U.S. FDA Acceptance Of Biologics License Application Fo..
09/26 AMGEN : FDA approves lower-cost alternative to biotech drug Humira
09/24 AMGEN : FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of ..
09/24 AMGEN : FDA Approves Amgen's AMJEVITA(TM) (Adalimumab-Atto) For Treatment Of Sev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/13DJGILEAD SCIENCES : Scientists Honored for Hep C Research
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
12:27p BIOTECH FORUM DAILY DIGEST : Notable Trial Failures; NASH Continues To Be Tough ..
09/27 Amgen's Kyprolis Clarion Call Falls On Deaf Ears
09/27 My 85 Stock Portfolio Evaluation Of Want To Buy Prices And Yields For Purchas..
09/27 Ligand Pharma down 9% on failure of Amgen's Phase 3 Kyprolis study
09/27 Shire returns rights to Humira biosimilar to Momenta Pharma
Financials ($)
Sales 2016 22 769 M
EBIT 2016 11 112 M
Net income 2016 7 441 M
Debt 2016 3 033 M
Yield 2016 2,28%
P/E ratio 2016 17,41
P/E ratio 2017 16,04
EV / Sales 2016 5,77x
EV / Sales 2017 5,33x
Capitalization 128 441 M
More Financials
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN, INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 191 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Chief Financial Officer & Executive Vice President
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Frank J. Biondi Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.5.73%129 863
GILEAD SCIENCES, INC.-21.68%106 391
ACTELION LTD19.91%18 591
More Results